ClostraBio, a biotechnology company developing next-generation probiotics to support gut health, today announced the full enrollment of a human clinical study evaluating its lead probiotic strain, Anaerostipes caccae CLB101™. This comes alongside a new distribution partnership with Maypro, a global ingredients supplier to the nutraceutical and health products industries.

The clinical study has enrolled 48 adult participants in a four-week, randomized, placebo-controlled trial designed to evaluate the safety and tolerability of CLB101™, while also generating insight into its potential to support gut health and intestinal barrier integrity. The study incorporates multiple endpoints, including subject-reported outcomes using the Gastrointestinal Symptom Rating Scale (GSRS), measurements of gut permeability, and biomarkers of inflammation and microbiome composition.

“This study represents an important milestone in our science-focused product development roadmap,” said Brian Meehan, PhD, Chief Scientific Officer of ClostraBio. “While CLB101™ has already undergone extensive toxicology evaluation, this trial allows us to further confirm safety and tolerability in humans and explore how this next-generation probiotic may support gut barrier function through a rigorous, hypothesis-driven clinical approach.” Study results are expected to be available in the first quarter of 2026.

In parallel with the clinical study, ClostraBio announced a new distribution partnership with Maypro, expanding access to CLB101™ for formulators and brand partners. The collaboration reflects growing market interest in differentiated, clinically supported, next-generation probiotic strains, and positions ClostraBio to meet increasing demand as additional scientific data become available.

“Maypro’s deep experience in ingredient distribution globally and its strong relationships across the nutrition industry make them an ideal partner as we scale,” said Ritu Shah, CEO of ClostraBio. “As we continue to generate clinical evidence behind CLB101™, this partnership helps ensure that our science-led innovation can reach the market efficiently and responsibly.”

ClostraBio’s momentum has also been recognized locally, with the company recently named an Up-and-Comer at the Chicago Innovation Awards, highlighting its contributions to advancing biotechnology innovation in the region.

About ClostraBio:

ClostraBio is leveraging a science driven, multi-pronged approach to address conditions of the lower gut, using novel biotechnology to harness natural pathways. The Company is developing a next-generation probiotic that produces butyrate in the lower gut to impact intestinal barrier function and promote gut health, as well as a novel polymeric prodrug platform designed to deliver small molecules to the lower gut. ClostraBio was spun out of the University of Chicago and is incubated at Portal Innovations.

About Maypro:

Maypro enhances health and well-being by delivering safe, science-backed nutraceutical ingredients and innovative nutritional solutions. By partnering with trusted global suppliers, Maypro helps make people healthier—one ingredient, one product, and one partnership at a time. Driven by integrity, innovation, and a relentless focus on quality, Maypro envisions a healthier and happier world powered by advanced nutrition. www.maypro.com

About Anaerostipes caccae CLB101™:

A next-generation probiotic strain isolated from healthy humans, CLB101™ is unique and highly differentiated from legacy probiotics in that as a strict anaerobe, it has capacity to directly produce butyrate to impact gut barrier integrity, immunity and microbiome balance*. CLB101™ has achieved self-affirmed GRAS status and is currently marketed in the US as a dietary supplement. https://clb101probiotic.com/

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108863927/en/